Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 26 November 2018, 13:33 HKT/SGT
Share:
    

Source: Mitsubishi Corporation
Mitsubishi Corporation Announces Capital Alliance with Rhelixa Co., Ltd.

TOKYO, Nov 26, 2018 - (JCN Newswire) - Mitsubishi Corporation (MC) is pleased to announce that it has entered into a capital alliance agreement with Rhelixa Co., Ltd. for 135 million yen via the acceptance of third-party allocation of shares.

Rhelixa is a biotechnology startup with strengths in analyzing epigenome information. As Japan's society ages, the number of patients with cancer, dementia and other chronic conditions associated with age are also on the rise. It is known that many of these conditions are caused by aberrant epigenetic regulations. Being fundamental mechanisms for every organism, however, these epigenetic regulations can be applied in analyzing these conditions and coming up with methods for treatment and prevention.

In addition, conducting epigenome analysis in animals and plants is expected to lead to the development of advanced cultivation and breeding technologies in agriculture, livestock and fishery that are more efficient and have less impact on the environment. In other words, epigenome analysis is expected to lead to the advancement of therapeutic and preventive technology and thereby contribute to the improving quality of life for many people.

Under the alliance, MC dispatches a director to Rhelixa and, by combining its broad business base, global networks and comprehensive capabilities with the proprietary technologies of Rhelixa, is aiming to build a new business model that will help improve Rhelixa's corporate value.

In addition, this alliance is being executed under the In-House Business Incubation Program introduced on a trial basis by MC's Living Essential Group in 2018. Its aim is to promote the development of businesses that contribute to the creation of consumer value and to human resource development. Through this and similar approaches, MC will continue to support the business initiatives of employees as it pursues the challenge of creating new value that will solve social issues.


Contact:
Mitsubishi Corporation
Telephone: +81 3 3210 2171
Facsimile: +81 3 5252 7705 



Topic: Press release summary
Sectors: Daily News, Venture Capital
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Mitsubishi Corporation Links

http://www.mitsubishicorp.com

https://ph.linkedin.com/company/mitsubishi-corporation

Mitsubishi Corporation
Jan 19, 2021 09:25 HKT/SGT
Mitsubishi Corporation: Commercial Operations Commence at Methanol / Dimethyl Ether Plant in Trinidad and Tobago
Dec 24, 2020 16:01 HKT/SGT
Vietnam Pilot Project Utilizing TradeWaltz Platform Adopted Under Government's Supply-Chain Diversification Scheme
Dec 8, 2020 15:01 HKT/SGT
MC Signs Rolling Stock Contracts with Myanma Railways
Nov 24, 2020 13:15 HKT/SGT
Mitsubishi Corporation Signs Contract with Egyptian Government for Phase 1 of Cairo Metro Line 4
Oct 30, 2020 23:10 HKT/SGT
Hitachi Rail and Mitsubishi Corp to Deliver Metro de Panama Line 3 worth JPY 92.0 Billion
Oct 28, 2020 09:30 HKT/SGT
Trials of Jointly Developed Compact LNG Filling System to Commence in Hokkaido
Oct 27, 2020 11:25 HKT/SGT
Mitsubishi Corporation: Cross-Industry Investment by Seven Enterprises in New TradeWaltz Platform
Oct 1, 2020 09:09 HKT/SGT
MC Commences Feasibility Study on Biometric Authentication Platform in Turkey
Sept 23, 2020 15:00 HKT/SGT
Mitsubishi Corporation: Use of CO2 in Concrete / Partnership with Blue Planet Systems Corporation
Sept 15, 2020 08:41 HKT/SGT
Mitsubishi Corporation and Surbana Jurong Joint Venture to Form Partnership with SinarMas Land to Advance Smart, Sustainable Transit-Oriented Developments in Indonesia
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: